Biogen Drug Sends Tau Into Reverse: An Alzheimer’s Breakthrough In The Making?

60% Reduction In Tau Exceeds Expectations

Phase I study and open-label extension results show a big drop in tau levels, which are more closely linked to Alzheimer’s symptoms than amyloid beta – setting up hopes of success in an ongoing Phase II study.

While Eisai and Biogen’s newly approved amyloid beta

targeting drug Leqembi (lecanemab) is raising hopes of progress against Alzheimer’s disease, Biogen has just released eye-catching early data which...